Adocia SA (FRA:A89)

Market Cap	92.48M +50.5%
Revenue (ttm)	3.85M -68.3%
Net Income	-16.59M
EPS	n/a
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	328
Open	4.670
Previous Close	4.682
Day's Range	4.670 - 4.670
52-Week Range	3.330 - 11.400
Beta	n/a
RSI	44.43
Earnings Date	Apr 21, 2026

About Adocia

Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; and BioChaperone LisPram, a combination of pramlintide and lispro, as well as M1Pram, a combinati...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2005
• Employees: 77
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: A89

Financial Performance

In 2025, Adocia's revenue was 3.85 million, a decrease of -68.26% compared to the previous year's 12.12 million. Losses were -16.59 million, 78.0% more than in 2024.